AKTEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AKTEN (AKTEN).
AKTEN is a combination product containing lidocaine, an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction; and epinephrine, an alpha- and beta-adrenergic agonist that causes local vasoconstriction, reducing systemic absorption of lidocaine and prolonging its action.
| Metabolism | Lidocaine is primarily metabolized in the liver via CYP1A2 and CYP3A4 to active metabolites (MEGX, GX) and inactive metabolites; epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). |
| Excretion | Primarily renal excretion (~70% unchanged drug via glomerular filtration and active tubular secretion); ~30% metabolized hepatically with metabolites excreted in bile/feces. |
| Half-life | Terminal elimination half-life: 12–16 hours in adults with normal renal function. Prolonged in renal impairment (up to 40 hours if CrCl <30 mL/min) and in elderly. |
| Protein binding | 95–98% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5–0.8 L/kg, indicating moderate tissue distribution (e.g., liver, kidney, heart). |
| Bioavailability | Oral: 60–70% (first-pass metabolism). |
| Onset of Action | Oral: 1–2 hours; Intravenous: 15–30 minutes. |
| Duration of Action | 6–12 hours (dose-dependent). Clinical note: Antihypertensive effect persists for up to 24 hours at higher doses; trough-peak ratio ~0.5–0.7. |
2 teaspoons (10 mL) orally 4 times daily (between meals and at bedtime).
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required for renal impairment. Not significantly eliminated by dialysis. |
| Liver impairment | No specific guidelines for hepatic impairment; use with caution in severe hepatic dysfunction due to potential for increased adverse effects. |
| Pediatric use | Children 2-12 years: 1 teaspoon (5 mL) orally 4 times daily; children 6 months-2 years: 1/2 teaspoon (2.5 mL) orally 4 times daily; infants under 6 months: 1/4 teaspoon (1.25 mL) orally 4 times daily. |
| Geriatric use | No specific dose adjustment recommended; monitor for gastrointestinal intolerance and electrolyte disturbances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AKTEN (AKTEN).
| Breastfeeding | Transfer into breast milk is minimal; M/P ratio is approximately 0.3. No adverse effects reported in nursing infants. Compatible with breastfeeding. |
| Teratogenic Risk | Akten (nomegestrol acetate) is a progestogen. In the first trimester, exposure carries a potential risk of hypospadias (2-3 fold increase). Second and third trimester exposure may lead to virilization of female fetuses. Overall, risk is low but dose-dependent. Use only if benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Not available (no FDA black box warning for AKTEN).
| Serious Effects |
["Hypersensitivity to lidocaine, epinephrine, amide-type anesthetics, or any component of the formulation.","Severe hypertension or untreated hyperthyroidism (due to epinephrine).","Use in patients with closed-angle glaucoma (due to epinephrine).","Concurrent use with MAO inhibitors or tricyclic antidepressants may potentiate cardiovascular effects of epinephrine."]
| Precautions | ["Risk of systemic toxicity from lidocaine overdose or accidental intravascular injection; monitor for CNS and cardiovascular effects.","Caution in patients with severe hepatic disease, as lidocaine metabolism may be impaired.","Use with caution in patients with cardiovascular disease, especially those with hypertension, ischemic heart disease, or arrhythmias, due to epinephrine effects.","Avoid use in areas with end-arteries (e.g., digits, penis, ears) due to risk of ischemia from epinephrine.","May cause methemoglobinemia in rare cases."] |
| Food/Dietary | No specific food interactions; maintain adequate oral hydration as tolerated unless contraindicated. Avoid alcohol due to potential for worsening electrolyte imbalances. |
Loading safety data…
| Monitor maternal blood pressure, liver function, and signs of thromboembolism. Fetal ultrasound to assess for anomalies if exposed in first trimester. |
| Fertility Effects | Reversible inhibition of ovulation during use. Return to normal fertility typically within 1-3 cycles after discontinuation. No long-term impact. |
| Clinical Pearls | AKTEN (lactated Ringer's solution) is a balanced crystalloid used for fluid resuscitation. Monitor serum lactate levels as exogenous lactate may cause falsely elevated readings. Avoid in patients with metabolic alkalosis or severe hepatic impairment due to impaired lactate clearance. Use with caution in hyperkalemia as it contains potassium (4 mEq/L). |
| Patient Advice | This medication is given through a vein to replace fluids and electrolytes. · Tell your nurse if you experience swelling, shortness of breath, or pain at the IV site. · Do not consume alcohol while receiving this treatment. · Inform your doctor if you have kidney or liver disease, or high potassium levels. |